

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 June 2023 (01.06.2023)



(10) International Publication Number
WO 2023/094818 A1

(51) International Patent Classification:

A61K 9/16 (2006.01) A61K 38/47 (2006.01)
A61M 15/08 (2006.01) A61P 1/00 (2006.01)

(21) International Application Number:

PCT/GB2022/052985

(22) International Filing Date:

25 November 2022 (25.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2117005.5 25 November 2021 (25.11.2021) GB
2208144.2 01 June 2022 (01.06.2022) GB
2213306.0 12 September 2022 (12.09.2022) GB

(71) Applicant: **OREXO AB** [SE/SE]; P.O. Box 303, 751 05
Uppsala (SE).

(72) Inventors: **SÄVMARKER, Jonas**; PO Box 303, 751 05
Uppsala (SE). **RÖNN, Robert**; PO Box 303, 751 05 Upp-
sala (SE).

(74) Agent: **MCNEENEY, Stephen Phillip**; Potter Clarkson,
The Belgrave Centre, Talbot Street, Nottingham Notting-
hamshire NG1 5GG (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING BIOPHARMACEUTICAL DRUG COMPOUNDS




Figure 8

(57) Abstract: According to the invention, there is provided a which composition is in the form of an amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of at least one biopharmaceutical drug compound; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrans (e.g. maltodextrins). Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Powder compositions may be produced by spray-drying the various components together in combination.

[Continued on next page]



WO 2023/094818 A1

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))